Drug
Inhaled Treprostinil
Inhaled Treprostinil: highest development phase Phase 3, developed by United Therapeutics. 6 trial records tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- United Therapeutics
Trials
| Drug | Phase | Indication |
|---|---|---|
| inhaled treprostinil NCT01557660 | Phase 3 | Pulmonary Arterial Hypertension |
| Inhaled Treprostinil NCT05943535 | Phase 3 | Progressive Pulmonary Fibrosis |
| Inhaled Treprostinil NCT05255991 | Phase 3 | Idiopathic Pulmonary Fibrosis |
| Inhaled treprostinil solution NCT03496623 | Phase 3 | Pulmonary Hypertension |
| Inhaled Treprostinil NCT04905693 | Phase 3 | Idiopathic Pulmonary Fibrosis |
| Inhaled Treprostinil NCT03012646 | Phase 2 | Pulmonary Hypertension |
Latest
No recent events.
Follow Inhaled Treprostinil on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.